Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia.
Stamatopoulos
K
K
Papadaki
T
T
Pontikoglou
C
C
Athanasiadou
I
I
Stavroyianni
N
N
Bux
J
J
Batsis
I
I
Pyrovolaki
K
K
Paterakis
G
G
Anagnostou
D
D
Anagnostopoulos
A
A
Papadaki
H A
HA
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects*; D017209:Apoptosis; D001853:Bone Marrow / Q000473:pathology / Q000502:physiology*; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D006410:Hematopoiesis; D006412:Hematopoietic Stem Cells / Q000502:physiology; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D016131:Lymphocyte Subsets / Q000276:immunology*; D008223:Lymphoma / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000473:pathology; D009503:Neutropenia / Q000139:chemically induced*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D016207:Cytokines; D000069283:Rituximab